Parkinson's Disease – Dyskinesia — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMovement DisordersParkinson's Disease – DyskinesiaSCE Neurology

A 72-year-old woman with a 3-year history of Parkinson's disease on co-careldopa develops peak-dose dyskinesia. What is the most appropriate medication to manage the dyskinesia?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Amantadine

Amantadine (an NMDA receptor antagonist) is the only oral medication with evidence for reducing peak-dose dyskinesia in Parkinson's disease, as recommended by NICE NG71. B: Increasing levodopa would worsen dyskinesia. C: Adding a dopamine agonist may worsen dyskinesia. D: Adding MAO-B inhibitor would increase dopaminergic stimulation. E: Adding COMT inhibitor would prolong levodopa effect and potentially worsen dyskinesia.

Reference: NICE NG71 Parkinson's Disease (2017)